Ready to Use Biosimilar Cell Lines
You do not want to wait until you have your desired biosimilar cell line in hands? UGA Biopharma promote a broad spectrum of Ready to Use Biosimilar Cell Lines including documentation which are ready to out-license to a collaboration partner. In addition UGA Biopharma can accelerate your way to success by providing an optimized bioprocess, downstream process and analytical data and methods.
Ready To Use Biosimilar Cell Lines read more


Full package ready for sales now:
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein


Aflibercept is a recombinant fusion protein with complex
post-translational modifications. Therefore deep understanding of biosimilar
development is required to develop a biosimilar like Aflibercept.






Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.




Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.




Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody).








This biosimilar project is under development at UGA Biopharma GmbH.












Under Development












Disclaimer


Back to products and services

Contact
UGA Biopharma GmbHNeuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail: info@ugabiopharma.com
Phone: +49(0)3302 / 2024900